|
The progress continued in 2008, when the Company and its partners identified ten new drug leads and brought two drugs into Investigational New Drug (IND) applications or clinical trials, one of which was the first LNA drug for an infectious disease. As Santaris Pharma and its partners deepen the understanding of LNA drugs in the coming years we hope to expand into new areas of disease providing hope for more and more patients. |